Eunice S. Wang, MD, spoke with CancerNetwork® on the 2024 European Hematology Affiliation (EHA) Congress about ongoing challenges within the acute myeloid leukemia (AML) subject, significantly these associated to managing TP53-mutated illness.
In accordance with Wang, chief of the Leukemia Service of the Division of Drugs at Roswell Park Complete Most cancers Middle in Buffalo, New York, focusing on TP53-mutant AML with immunotherapy continues to be a problem within the subject following displays on information associated to remedies such because the anti-CD47 agent magrolimab. Knowledge offered on the assembly confirmed that remedy regimens together with magrolimab plus azacitidine didn’t meet the first finish factors amongst sufferers with myelodysplastic syndrome within the section 3 ENHANCE examine (NCT04313881)1 and amongst these with AML within the section 3 ENHANCE-3 examine (NCT05079230).2
Wang said that future conferences might assist handle whether or not immunotherapies, bispecific brokers, or CAR T-cell therapies can impression the AML remedy paradigm.
Transcript:
TP53 nonetheless stays a problem [in AML]. We’ve been considerably dissatisfied. We’ve been excited yearly or so solely to be dissatisfied. [Regarding] the info on the market, I don’t see something that’s significantly focusing on TP53 mutations [in] sufferers. Immunotherapy additionally stays a problem. We had thought that as a result of most of our typical chemotherapy brokers don’t work that we might see some impression of immunotherapeutics in TP53-mutant AML. For instance, the current failure of magrolimab being offered at this EHA assembly with the outcomes of the ENHANCE trials, that are a fantastic database for the efficacy of an [azacitidine combination] however didn’t present any enchancment in an [azacitidine combination] with magrolimab, significantly in sufferers with TP53-mutant illness. That also stays a problem, and we’ll have to be trying ahead to future conferences as to how that’s being addressed and whether or not immunotherapeutic brokers, bispecifics, and CAR T-cell remedy have but to affect our remedy paradigms as of now for this difficult-to-treat myeloid malignancy.
References
- Sallman D, Garcia-Manero G, Daver N, et al. Magrolimab (Magro) + azacitidine (AZA) vs placebo (PBO) + AZA in sufferers (PTs) with untreated higher-risk (HR) myelodysplastic syndromes (MDS): section 3 ENHANCE examine closing evaluation. Introduced on the 2024 European Hematology Affiliation (EHA) Congress; June 13-16, 2024; Madrid, Spain. Summary S181.
- Daver N, Vyas P, Huls G, et al. Magrolimab vs placebo together with venetoclax and azacitidine in beforehand untreated sufferers with acute myeloid leukemia who’re ineligible for intensive chemotherapy: the ENHANCE-3 examine. Introduced on the 2024 European Hematology Affiliation (EHA) Congress; June 13-16, 2024; Madrid, Spain. Summary S138.
